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Introduction
============

Endovascular treatment (EVT) is less invasive and safer, and it is regarded as a first-line therapy for femoropopliteal (FP) lesions^[@bib1],\ [@bib2])^. For EVT of complex lesions, such as TransAtlantic Inter-Society Consensus (TASC II) types C or D, the primary patency rate at 12 months after self-expandable stent placement is reportedly 66%--78%^[@bib3]--[@bib6])^, which is acceptable. The intraluminal and subintimal approaches are selected in EVT for long occlusive lesions. Although the clinical outcomes after the subintimal approach for long occlusive lesions have been reported^[@bib6]--[@bib9])^, relatively few studies have investigated the clinical outcomes after the intraluminal approach for such lesions, and the outcomes of the intraluminal approach has not yet been accurately evaluated by intravascular ultrasound (IVUS). Therefore, the aim of this study was to evaluate the relationship between preprocedural and postprocedural IVUS findings and restenosis at 12 months after stent implantation for long occlusive lesions using the intraluminal approach.

Methods
=======

Patients
--------

This was a non-randomized, retrospective, single-center study. Between April 2007 and December 2014, EVT was performed for 925 *de novo* FP lesions at our hospital, of which 876 were excluded because of acute/subacute lower-limb ischemia (*n* = 12), stenotic or short (\< 10 cm) occlusive lesions (*n* = 660), EVT by the subintimal approach (*n* = 12), procedural failure (*n* = 14), EVT with angioplasty alone (*n* = 46), non full covered stents (*n* = 14), disuse of IVUS (*n* = 80), use of drug eluting stent (DES) (*n* = 8), death/major amputation/dropout within 12 months (*n* = 26), or inadequate IVUS data (*n* = 4). Therefore, 45 patients (49 lesions) who underwent bare metal stent (BMS) implantation for long occlusive FP lesions (occlusion length \> 10 cm) using the intraluminal approach were included for analysis (**[Fig. 1](#F1){ref-type="fig"}**). Restenosis according to duplex ultrasonography or angiographic criteria was observed in 14 lesions within 12 months (restenosis rate = 29%). These 45 patients were divided into two groups: restenosis and non-restenosis groups. All patients were on exercise and drug therapy, and had symptoms corresponding to categories 2--6 of the Rutherford classification^[@bib1])^. When angiography revealed occlusion of the FP vessels, vascular specialists (including vascular surgeons and interventional cardiologists) decided whether EVT was appropriate. The present study was conducted in accordance with the tenets of the Declaration of Helsinki and all patients submitted informed consent to participate in this study.

![Study Flowchart\
EVT: endovascular therapy.\
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Interventions
-------------

The crossover or ipsilateral approach was used for EVT. 6-Fr or 7-Fr sheaths were inserted and unfractionated heparin (5000 U) was injected intra-arterially. A microcatheter or an over-the-wire balloon was used as a support for advancing a 0.014-inch guidewire to the occluded site. The procedure was performed such that the guidewire was passed through the true lumen of the vessel as much as possible, as confirmed by body surface echography and IVUS, as needed. In cases in which it was not possible to pass the guidewire antegradely, we switched to a retrograde-approach via the popliteal or tibial artery^[@bib9],\ [@bib10])^. After a 0.014-inch guidewire was passed through the target lesion, IVUS images were recorded by manual pullback through the study segment at a uniform and steady rate. If it was not possible to cross the lesion with the IVUS catheter, balloon dilatation was performed with a 3-mm-diameter balloon prior to IVUS recording. A second attempt to access the intraplaque route was up to the discretion of the operator when the guidewire was passed through the subintimal or intramedial route. BMSs (Zilver 518 stent; Cook Medical, Bloomington, IN, USA; S.M.A.R.T stent; Cordis Endovascular, Warren, NJ, USA) were implanted so that it fully covered the lesion, meaning that the stents were implanted from angiographic normal-to-normal segments. A stent with a diameter 1--2 mm larger than the reference vessel diameter proximal to the target lesion was selected. When two or more stents were used for a long lesion, the overlap was ≤ 10 mm. Predilatation and postdilatation was performed routinely. At the end of the procedure, IVUS images were recorded again using commercially available IVUS consoles (s5™ Imaging System; Volcano Corporation, Rancho Cordova, CA, USA or VISIWAVE™; Terumo Corporation, Tokyo, Japan) and a phased-array 20-MHz IVUS catheter (Eagle Eye Gold; Volcano Corporation) or 35-MHz IVUS catheter (View it; Terumo Corporation).

Medical Therapy
---------------

Dual antiplatelet therapy (DAPT) with aspirin (100 mg/day) plus clopidogrel (75 mg/day), ticlopidine (200 mg/day), or cilostazol (200 mg/day) was started at least 3 days before stenting and was continued for at least 2 months afterward.

IVUS Analysis
-------------

For analysis of the IVUS data, the s5™ Imaging System (Volcano Corporation) and VISIWAVE™ (Terumo Corporation) were used. Two experienced observers who were unaware of the clinical and angiographic findings performed all IVUS analyses. The IVUS parameters measured or calculated were route of chronic total occlusion (CTO) (intraplaque, subintimal, and intramedial)^[@bib11])^, maximum calcification arc, maximum and minimum stent cross-sectional area (CSA), proximal and distal CSA of the external elastic membrane (EEM), luminal CSA, plaque burden, reference luminal CSA, reference diameter, stent/reference diameter ratio, stent expansion ratio, radial stent symmetry index, and axial stent symmetry index. The proximal and distal reference segments selected for analysis were the most normal-looking cross-sections within 10 mm of the proximal and distal margins of the stent before the origin of any large side branches^[@bib12])^. Stent-edge dissection was also investigated. The proportion of stents placed using the intraplaque route within the CTO was calculated as IVUS flame numbers of the guidewire and IVUS transducer being located via the intraplaque route divided using the total IVUS flame number of the whole CTO route. The proportions of placements via the subintimal/intramedial routes were calculated in the same manner.

Definitions
-----------

Diabetes mellitus (DM) was defined as a condition requiring treatment with oral hypoglycemic drugs or insulin, or as a casual plasma glucose concentration of \> 200 mg/dl or HbA1c of \> 6.5%. Chronic kidney disease was defined as a glomerular filtration rate of \< 60 ml/min/1.73 m^2^. Coronary artery disease was defined as documented angina pectoris, previous myocardial infarction, or a history of coronary revascularization. Cerebrovascular disease was defined as previous stroke, transient ischemic attacks, carotid artery revascularization, or intracranial hemorrhage^[@bib13])^. The definition of critical limb ischemia was the same as described elsewhere^[@bib14])^. Below-the-knee (BTK) runoff was assessed by angiography after stent placement. Poor runoff was defined as runoff in one or no BTK vessel^[@bib15])^. The intraluminal approach indicates EVT using a 0.014-inch or 0.018-inch guidewire with a supporting catheter^[@bib7])^. Stenting was classified as successful if angiography demonstrated that residual stenosis was ≤ 30% without flow-limiting dissection^[@bib16])^. Restenosis was defined as a peak systolic velocity ratio of \> 2.4 on duplex ultrasonography or \> 50% diameter stenosis or occlusion on quantitative vascular angiography^[@bib17])^. Target lesion revascularization (TLR) was defined as the need for repeated procedures (endovascular or surgical) because of a problem arising from the lesion (+1 cm proximally and distally to include edge phenomena)^[@bib6])^. The definition of stent thrombosis was the same as described elsewhere^[@bib18])^. The definitions of IVUS parameters followed those of a previous report^[@bib19])^. Wire passage in occlusive lesions was classified according to IVUS findings: intraplaque, inside the plaque; subintimal, between the plaque and media; and intramedial, between the media and adventitia^[@bib11])^. Stent-edge dissection was defined as dissection at a stent edge (\< 5 mm proximal or distal to the stent margin)^[@bib16],\ [@bib20])^.

Clinical Follow-Up
------------------

Postprocedural evaluation of symptoms, measurement of the ankle--brachial index (ABI), and duplex ultrasonography were performed at 1, 3, 6, 9, and 12 months after stent placement. When duplex ultrasonography suggested restenosis, angiography was performed for confirmation.

Statistical Analysis
--------------------

Statistical analysis was performed using JMP software (version 10.0.0, SAS Institute, Cary, NC, USA). Continuous variables with normal distributions are presented as the means ± standard deviations. Categorical data are presented as frequencies. Continuous variables were compared using the unpaired Student\'s *t*-test or the Mann--Whitney *U*-test. Categorical data were compared with the chi-squared test or Fisher\'s exact test. Univariate and multivariate logistic regression analysis were performed to identify predictors of restenosis. Variables with a probability (*p*) value of \< 0.05 on univariate analysis were entered into a multivariate regression model. Receiver operating characteristic (ROC) analysis was performed to determine the optimal cutoff value of the within-CTO intramedial route proportion and distal lumen CSA to predict restenosis at 12 months after stent placement, with each cutoff point being selected to yield the highest value for the sum of sensitivity and specificity. The area under the ROC curve (AUC) was used as a measure of the accuracy of each parameter. In all analyses, *p* values of \< 0.05 were considered statistically significant.

Results
=======

Patients and Procedural Characteristics
---------------------------------------

In the present study, 49 lesions in 45 patients were investigated. Restenosis was detected in 14 lesions (29%) at 12 months after stent placement. Baseline characteristics are shown in **[Table 1](#T1){ref-type="table"}**. There were no significant differences in the percentage of patients aged \> 70 years; male:female ratio; or prevalence of DM, dialysis, and critical limb ischemia between the two groups. Regarding medications, cilostazol use and continuation of DAPT at 2 months were also similar between the two groups. Baseline lesion and procedural characteristics are shown in **[Table 2](#T2){ref-type="table"}**. A cross-over approach was chosen in 40 lesions (81%) and a 6 Fr sheath was most commonly used (90%). A bidirectional approach was used in 16 lesions (33%). The percentages of TASC II type D lesions and lesions extending to the popliteal artery were 43% and 22%, respectively. Mean lesion length, CTO length, and total stent length were 222 ± 46, 177 ± 59, and 261 ± 68 mm, respectively. There were no significant differences in these variables between the two groups.

###### Patient Characteristics

  Variables                                  Total       Restenosis   Non-restenosis   *p* value
  ------------------------------------------ ----------- ------------ ---------------- -----------
  Age \> 70 years (%)                        23 (51)     4 (31)       19 (59)          0.08
  Female (%)                                 14 (31)     5 (38)       9 (28)           0.50
  Hypertension (%)                           41 (91)     13 (100)     28 (88)          0.18
  Dyslipidemia (%)                           20 (44)     5 (38)       15 (47)          0.61
  Current smoker (%)                         13 (29)     6 (46)       7 (22)           0.10
  Diabetes mellitus (%)                      21 (47)     7 (54)       14 (44)          0.54
  Chronic renal disease (%)                  26 (58)     10 (77)      16 (50)          0.09
  Dialysis (%)                               8 (18)      4 (31)       4 (13)           0.15
  Coronary artery disease (%)                14 (31)     4 (31)       10 (31)          0.97
  Cerebrovascular disease (%)                5 (11)      0            5 (16)           0.13
  EF \< 40% (%)                              2 (4)       1 (8)        1 (3)            0.50
  Critical limb ischemia (%)                 16 (36)     3 (23)       13 (41)          0.27
  Medications                                                                          
      Aspirin (%)                            43 (96)     13 (100)     30 (94)          0.36
      Thienopyridines (%)                    35 (78)     10 (77)      25 (78)          0.93
      Cilostazol (%)                         16 (34)     5 (38)       11 (34)          0.80
      No. of anti-platelets                  2.1 ± 0.5   2.1 ± 0.6    2.1 ± 0.5        0.94
      Warfarin (%)                           10 (22)     5 (38)       5 (16)           0.09
      Statin (%)                             17 (38)     3 (23)       14 (44)          0.19
      Continuation of DAPT at 2 months (%)   40 (89)     11 (85)      29 (91)          0.56

EF: ejection fraction

DAPT: dual antiplatelet therapy

###### Lesion and Procedural Characteristics

  Variables                                  Total              Restenosis        Non-restenosis     *p* value
  ------------------------------------------ ------------------ ----------------- ------------------ -----------
  Lesion length (mm)                         222 ± 46           231 ± 45          219 ± 47           0.43
  CTO length (mm)                            177 ± 59           196 ± 58          169 ± 59           0.15
  TASC II type D (%)                         21 (43)            6 (43)            15 (43)            1.0
  Involving popliteal lesion (%)             11 (22)            2 (14)            9 (26)             0.39
  Calcified lesion (%)                       8 (16)             2 (14)            6 (17)             0.81
  Poor runoff (%)                            22 (45)            8 (57)            14 (40)            0.28
  Crossover approach (%)                     40 (81)            12 (86)           28 (80)            0.64
  Bidirectional approach (%)                 16 (33)            4 (29)            12 (34)            0.70
  Sheath size (%)                                                                                    
      7/6 Fr                                 5/44 (10/90)       0/14 (0/100)      5/30 (14/86)       0.14
      No. of guidewires                      2.6 ± 0.8          2.4 ± 0.6         2.6 ± 0.9          0.31
      Predilatation (%)                      49 (100)           14 (100)          35 (100)           N.E
      Predilatation balloon diameter (mm)    4.0 ± 0.5          3.8 ± 0.4         4.0 ± 0.5          0.12
      Maximum pressure (atm)                 8.9 ± 3.0          8.9 ± 3.5         8.9 ± 2.8          1.0
      Postdilatation (%)                     49 (100)           14 (100)          35 (100)           N.E
      Postdilatation balloon diameter (mm)   5.3 ± 0.8          4.9 ± 0.7         5.4 ± 0.8          0.07
      Maximum pressure (atm)                 11.3 ± 3.4         11.0 ± 3.0        11.4 ± 3.5         0.71
      Stent diameter (mm)                    6.9 ± 0.8          6.7 ± 0.8         7.0 ± 0.7          0.16
      Total stent length (mm)                261 ± 68           279 ± 72          254 ± 66           0.25
      No. of stents                          2.7 ± 0.7          2.6 ± 0.6         2.7 ± 0.8          0.85
  Type of stents (%)                                                                                 
      SMART/Zilver 518/mix                   40/5/4 (82/10/8)   12/1/1 (86/7/7)   28/4/3 (80/11/9)   0.88
      Procedural time (min)                  108 ± 49           115 ± 61          104 ± 45           0.50
      Fluoroscopic time (min)                45 ± 27            43 ± 30           46 ± 26            0.70
      Pre diameter stenosis (%)              100                100               100                N.E
      Post diameter stenosis (%)             16.6 ± 8.3         13.4 ± 6.1        17.8 ± 8.8         0.10
      Pre ABI                                0.58 ± 0.21        0.56 ± 0.20       0.58 ± 0.21        0.72
      Post ABI                               0.91 ± 0.17        0.92 ± 0.20       0.91 ± 0.16        0.74

CTO: chronic total occlusion

TASC: trans-Atlantic Intersociety Consensus.

ABI: ankle--brachial index.

IVUS Findings
-------------

Preprocedural and postprocedural IVUS findings are detailed in **[Table 3](#T3){ref-type="table"}**. The percentages of the intraplaque, subintimal, and intramedial routes were 73% ± 28%, 18% ± 19%, and 9% ± 14%, respectively. The whole intraplaque route was gained in 15 lesions (31%). The proportion of the intraplaque route was significantly lower and the proportion of the intramedial route was significantly higher in the restenosis group (60% ± 32% vs. 78% ± 26%, *p* \< 0.05, and 16% ± 14% vs. 7% ± 13%, *p* \< 0.05, respectively). The maximum and minimum stent CSA were similar between the two groups (22.8 ± 5.5 vs. 24.4 ± 6.8 mm^2^, *p* = 0.43, and 12.3 ± 2.8 vs. 13.2 ± 3.5 mm^2^, *p* = 0.36, respectively). There were no significant differences in the proximal EEM CSA and proximal lumen CSA, and the distal EEM CSA (54.5 ± 23.1 vs. 54.1 ± 21.9 mm^2^, *p* = 0.95, 28.6 ± 10.5 vs. 29.6 ± 13.6 mm^2^, *p* = 0.80, and 28.3 ± 9.5 vs. 32.9 ± 9.7 mm^2^, *p* = 0.13, respectively). However, the distal lumen CSA was significantly smaller in the restenosis group (15.2 ± 4.7 vs. 19.0 ± 5.8 mm^2^, *p* \< 0.05). The radial symmetry index, axial symmetry index, stent expansion ratio, stent/vessel diameter, and the rate of stent-edge dissection were similar between the two groups.

###### IVUS findings

  Variables                               Total         Restenosis    Non-restenosis   *p* value
  --------------------------------------- ------------- ------------- ---------------- -----------
  Maximum arc of calcification (degree)   126 ± 147     129 ± 145     124 ± 150          0.93
  Route of CTO                                                                         
      Intraplaque (%)                     73 ± 28       60 ± 32       78 ± 26            0.0498
      Subintimal (%)                      18 ± 19       24 ± 21       15 ± 18            0.17
      Intramedial (%)                     9 ± 14        16 ± 14       7 ± 13             0.0318
      Whole intraplaque route (%)         15 (31)       2 (14)        13 (37)            0.12
  Reference segment                                                                    
      Proximal EEM CSA (mm^2^)            54.2 ± 22.0   4.5 ± 23.1    54.1 ± 21.9        0.95
      Proximal lumen CSA (mm^2^)          29.3 ± 12.7   28.6 ± 10.5   29.6 ± 13.6        0.80
      Distal EEM CSA (mm^2^)              31.6 ± 9.8    28.3 ± 9.5    32.9 ± 9.7         0.13
      Distal lumen CSA (mm^2^)            17.9 ± 5.7    15.2 ± 4.7    19.0 ± 5.8         0.0312
      Maximum stent CSA (mm^2^)           24.0 ± 6.5    22.8 ± 5.5    24.4 ± 6.8         0.43
      Minimum stent CSA (mm^2^)           12.9 ± 3.3    12.3 ± 2.8    13.2 ± 3.5         0.36
      Radial symmetry index               0.69 ± 0.16   0.73 ± 0.13   0.67 ± 0.17        0.31
      Axial symmetry index                0.53 ± 0.13   0.54 ± 0.14   0.53 ± 0.12        0.78
      Stent expansion ratio               0.59 ± 0.19   0.59 ± 0.18   0.59 ± 0.19        0.94
      Stent/vessel diameter               1.31 ± 0.17   1.30 ± 0.17   1.31 ± 0.17        0.98
      Stent-edge dissection               3 (6)         2 (14)        1 (3)              0.13

IVUS: intravascular ultrasound.

CTO: chronic total occlusion.

CSA: cross-sectional area.

EEM: external elastic membrane.

Univariate and Multivariate Logistic Regression Analysis of Restenosis
----------------------------------------------------------------------

Univariate and multivariate logistic regression analysis were performed to identify independent predictors of restenosis. Within-CTO intramedial route proportion and distal lumen CSA were entered into the multivariate model. Within-CTO intraplaque route proportion was not entered into that because of the associations with the within-CTO intramedial route proportion. As shown in **[Table 4](#T4){ref-type="table"}**, on multivariate analysis, within-CTO intramedial route proportion \[odds ratio (OR) = 1.05; 95% confidence interval (CI) = 1.01--1.11, *p* \< 0.05\] and distal lumen CSA (OR = 0 .85; 95% CI = 0.72--0.98, *p* \< 0.05) were independent predictors of restenosis.

###### Logistic Regression Analysis of Restenosis

  Variables           Univariate analysis   Multivariate analysis                       
  ------------------- --------------------- ----------------------- ------------------- ------
  Intramedial route   1.05 (1.01--1.10)     0.02                    1.05 (1.01--1.11)   0.03
  Distal lumen CSA    0.87 (0.74--0.98)     0.02                    0.85 (0.72--0.98)   0.02

OR: odds ratio.

CI: confidence interval.

CSA: cross-sectional area.

ROC Analysis
------------

The results of ROC analysis of within-CTO intramedial route proportion and distal lumen CSA are shown in **[Fig. 2](#F2){ref-type="fig"}**. The AUC for within-CTO intramedial route proportion was 0.691 (95% CI = 0.519--0.863, *p* \< 0.05) and the best cutoff value of within-CTO intramedial route proportion to predict restenosis within 12 months after stent placement was 14.4%, which had a sensitivity of 64.3% and a specificity of 80.0%. In the present series, the within-CTO intramedial route proportion was \> 14.4% in 30.6% of all lesions. On the other hand, the AUC for the distal lumen CSA was 0.707 (95% CI = 0.550--0.864, *p* \< 0.05) and the best cutoff value of distal lumen CSA to predict restenosis was 17.7 mm^2^, which had a sensitivity of 92.9% and a specificity of 57.1%. The distal lumen CSA was \< 17.7 mm^2^ in 55.1% of all lesions.

![Receiver-operating characteristic analysis of the proportion via the intramedial route and distal reference lumen CSA for developing restenosis\
CSA: cross-sectional area.\
AUC: area under the curve.\
CI: confidence interval.](jat-24-477-g002){#F2}

Clinical Outcomes
-----------------

Clinical outcome at 12 months are shown in **[Table 5](#T5){ref-type="table"}**. The rates of freedom from restenosis, reocclusion, and TLR were 71%, 82%, and 82%, respectively. Stent thrombosis occurred in only 2 (4%) patients.

###### Clinical outcome at 12 months

  Variables                      *n* = 49
  ------------------------------ ----------
  Freedom from restenosis (%)    35 (71)
  Freedom from reocclusion (%)   40 (82)
  Freedom from TLR (%)           40 (82)
  Stent thrombosis (%)           2 (4)

TLR: target lesion revascularization

Discussion
==========

Although there are a few reports on the clinical outcomes of the intraluminal approach for long FP lesions^[@bib7],\ [@bib8],\ [@bib21])^, the present study is the first to evaluate the relationship between IVUS findings and restenosis after placement of BMSs for repair of long occlusive FP lesions via the intraluminal approach.

Relationship between the Within-CTO Intramedial Route Proportion and Restenosis
-------------------------------------------------------------------------------

Within-CTO intraplaque route proportion was significantly lower and the proportion of intramedial route was significantly higher in the restenosis group. Multivariate logistic regression analysis revealed that within-CTO intramedial route proportion was a predictor of restenosis within 12 months after EVT. The underlying reason was not investigated in the present study. However, two possible reasons can be suggested. One is that medial injury seems to contribute to restenosis. The previous study reported that a damage of internal elastic lamella was associated with increased neointimal proliferation, inflammation, and cellularity compared to *de novo* atherosclerosis. This correlates with a biological response of cellular proliferation and repair resulting from deep injury leading to restenosis^[@bib22]--[@bib24])^. The other possibility is that stent implantation via the intramedial route might cause insufficient stent expansion, leading to unfavorable short-term results, which may contribute to loss of patency. The present study also suggested that achieving a within-CTO intramedial route in \< 14.4% of lesions was important and would improve primary patency. Using the subintimal approach, the guidewire was within the plaque in \< 30% of lesions at the middle and distal occlusive segments^[@bib11],\ [@bib25])^. In addition, the guidewire was passed completely in the subintimal or intramedial route in 32 (64%) of 50 cases, suggesting that it is difficult to maneuver the wire back to within the plaque once it enters the subintimal or intramedial space^[@bib25])^. The subintimal approach seems to be disadvantageous to decrease within-CTO intramedial route proportion because the maneuver of a 0.035-inch guidewire is uncontrollable. On the other hand, by improvement in procedures and devices, the intraluminal approach enables a lower proportion of stent placements via the intramedial route; thus, there is a possibility to improve the clinical outcomes of long occlusive FP lesions. In addition, placement via the intramedial route seems to be avoided to ensure the safety of various atherectomy devices^[@bib22])^.

Relationship between Distal Lumen CSA and Restenosis
----------------------------------------------------

The distal lumen CSA was significantly smaller in the restenosis group than in the non-restenosis group and multivariate logistic regression analysis revealed that the distal lumen CSA was a predictor of restenosis within 12 months after EVT. Several studies revealed that the distal reference lumen/EEM CSA was useful to predict TLR after stent implantation for FP lesions^[@bib16],\ [@bib18],\ [@bib19])^, which is consistent with our results. The results of the present study suggest that restenosis risk after EVT for long occlusive lesions with small vessel is high. The ROC analysis showed that using the distal lumen CSA with a cutoff value of 17.7 mm^2^ could predict restenosis at 12 months after stent placement with a sensitivity of 92.9% and a specificity of 57.1% (**[Fig. 2](#F2){ref-type="fig"}**). For long occlusive lesions with a distal lumen CSA of \< 17.7 mm^2^, the primary patency at 12 months was only 55.6% in our study. This outcome is far inferior to that of autologous vein bypass grafting, which is reportedly 81%--88% at 12 months^[@bib26]--[@bib29])^. However, the effectiveness of other devices, such as drug-coated balloons, atherectomy devices, and laser ablation has not been investigated for long occlusive lesions with small vessels. Consequently, at the present time, autologous vein bypass surgery should be considered more strongly for long occlusive lesions with small vessels.

Limitations
-----------

There were several limitations to this study. First, this study was retrospective and included a small number of patients. Second, each operator decided whether to use DES or BMS, and whether or not to use IVUS; thus, there was the potential for bias. Third, each within-CTO route proportion might be overestimated or underestimated because the IVUS examination was performed by manual pullback. Finally, evaluation of the IVUS findings was not performed by an independent core laboratory.

Conclusion
==========

When the intraluminal approach was selected for treatment in long occlusive FP lesions, the whole intraplaque route was achieved in 31%. If IVUS detects a proportion of the intramedial route within the CTO of \> 14.4% or a distal lumen CSA of \< 17.7 mm^2^, restenosis is more likely.
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